Author

Pengcheng Miao

Institution: Southeast University

Observed institution: Southeast University

ORCID: 0000-0001-6369-7974

Observed ORCID: 0000-0001-6369-7974

OpenAlex ID: A5026212289

Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China

2023 · Minmin Zhao, Shanhu Qiu, et al. · Targeted Oncology · 21

An Unsupervised Deep Learning-Based Model Using Multiomics Data to Predict Prognosis of Patients with Stomach Adenocarcinoma

2022 · Sizhen Chen, Yiteng Zang, et al. · Computational and Mathematical Methods in Medicine · 18

Prevalence and factors influencing long COVID among primary healthcare workers after epidemic control policy adjustment in Jiangsu, China

2024 · Hualing Chen, Yongkang Qian, et al. · BMC Infectious Diseases · 6

Primary healthcare workers’ COVID-19 infection status following implementation of adjusted epidemic prevention and control strategies: a cross-sectional study in Jiangsu, China

2023 · Beier Lu, Rongji Ma, et al. · Frontiers in Public Health · 4

Integrated Identification and Immunotherapy Response Analysis of the Prognostic Signature Associated With m6A , Cuproptosis‐Related, Ferroptosis‐Related lncRNA in Endometrial Cancer

2024 · Yongkang Qian, Hualing Chen, et al. · Cancer Reports · 3

Duration and severity of COVID ‐19 symptoms among primary healthcare workers: A cross‐sectional survey

2024 · Rongji Ma, Beier Lu, et al. · Journal of Advanced Nursing · 2

A propensity score matched analysis of COVID-19 ongoing symptoms in primary medical staff members with different levels of stress in Jiangsu Province, China

2024 · Hualing Chen, Yongjie Zhang, et al. · Heliyon · 1

Author response for "Duration and severity of COVID ‐19 symptoms among primary healthcare workers: A cross‐sectional survey"

2024 · Rongji Ma, Beier Lu, et al. · Publons reviews and discussion

Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT).

2023 · Minmin Zhao, Yang Shen, et al. · Journal of Clinical Oncology

Works count: 9

Citation count: 55

H-index: 4

I10-index: 2